Table 2.
Factors associated with low BMD and fracture at univariate analysis
| |
BMD < −1SD |
Fracture |
||
|---|---|---|---|---|
| OR [95% CI] | P | OR [95% CI] | P | |
| Menopause |
5.29 [1.83; 15.27] |
0.002 |
2.1 [0.68; 6.53] |
0.2 |
| Age, years |
1.06 [1.03; 1.1] |
<0.001 |
1.09 [1.05; 1.14] |
<0.001 |
| Calcium intake <500 mg/d |
4.28 [1.89; 9.72] |
<0.001 |
2.2 [0.93; 5.18] |
0.072 |
| Stage NHYA 3 or 4 |
3.34 [1.3; 8.54] |
0.012 |
3.18 [1.23; 8.2] |
0.017 |
| Disease duration |
1.05 [1; 1.1] |
0.047 |
1 [0.95; 1.06] |
0.9 |
| Cumulative CS dose |
1.15 [0.98; 1.36] |
0.088 |
1.2 [0.99; 1.44] |
0.059 |
| Current CS treatment |
1.68 [0.83; 3.4] |
0.15 |
2.63 [1.08; 6.37] |
0.033 |
| Vitamin D supplements |
3.82 [1.66; 8.8] |
0.002 |
2.07 [0.87; 4.95] |
0.1 |
| BP treatment |
3.03 [1.44; 6.36] |
0.003 |
1.83 [0.8; 4.15] |
0.15 |
| ESR >10 mm/h |
2.49 [1.1; 5.62] |
0.028 |
1.38 [0.55; 3.46 |
0.5 |
| Lymphocytes >1,000/mm3 |
0.45 [0.21; 0.94] |
0.033 |
1.19 [0.5; 2.85] |
0.7 |
| Creatinine clearance, ml/mn |
0.99 [0.98; 1] |
0.034 |
0.97 [0.95; 0.99] |
<0.001 |
| 25(OH)D serum level |
|
|
|
|
| 25(OH)D ≤10 ng/ml |
1 |
- |
1 |
- |
| 10 < 25(OH)D <20 ng/ml |
0.48 [0.21; 1.09] |
0.079 |
1.24 [0.45; 8.23] |
0.67 |
| 25(OH)D >20 ng/ml |
2.00 [0.8; 4.97] |
0.13 |
2.94 [1.05; 8.23] |
0.04 |
| Serum PTH level, pmol/l |
|
|
|
|
| Fracture/low BMD | 4.39 [1.86; 10.37] | <0.001 | 4.39 [1.86; 10.37] | <0.001 |
BMD, bone mineral density; BP, bisphosphonates; CS, Corticosteroids; ESR, erythrocyte sedimentation rate; PTH, parathyroid hormone; NYHA, New York Heart Association.